Human Investing LLC purchased a new position in shares of STERIS plc (NYSE:STE – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund purchased 152 shares of the medical equipment provider’s stock, valued at approximately $31,000.
Several other hedge funds have also made changes to their positions in STE. Magnolia Capital Advisors LLC increased its stake in STERIS by 1.9% during the 4th quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider’s stock worth $521,000 after buying an additional 48 shares during the period. SkyView Investment Advisors LLC grew its stake in shares of STERIS by 1.6% in the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock worth $765,000 after acquiring an additional 51 shares in the last quarter. Park Edge Advisors LLC increased its position in shares of STERIS by 1.1% during the fourth quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider’s stock worth $958,000 after acquiring an additional 51 shares during the period. Opal Wealth Advisors LLC raised its stake in shares of STERIS by 5.7% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,118 shares of the medical equipment provider’s stock valued at $230,000 after acquiring an additional 60 shares in the last quarter. Finally, Sage Private Wealth Group LLC boosted its holdings in STERIS by 4.1% in the fourth quarter. Sage Private Wealth Group LLC now owns 1,537 shares of the medical equipment provider’s stock valued at $316,000 after purchasing an additional 61 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.
Insider Buying and Selling
In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.14% of the stock is currently owned by company insiders.
STERIS Stock Up 0.1 %
STERIS (NYSE:STE – Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.
STERIS Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. STERIS’s dividend payout ratio (DPR) is presently 48.41%.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $240.00 price target on shares of STERIS in a research note on Thursday, February 6th. Piper Sandler increased their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Friday, November 8th. Finally, StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average price target of $258.75.
Check Out Our Latest Stock Analysis on STERIS
STERIS Profile
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
- Five stocks we like better than STERIS
- Overbought Stocks Explained: Should You Trade Them?
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- Election Stocks: How Elections Affect the Stock Market
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- Roth IRA Calculator: Calculate Your Potential Returns
- Conflicting Signals: Tempus AI’s Stock Market Rally
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.